Every clinical trial and post-marketing safety review for GLP-1 receptor agonists shows the same broad pattern: most side effects are gastrointestinal, most are mild-to-moderate, and most resolve within 8–10 weeks of consistent dosing. A smaller subset are serious — and those are the ones to monitor for.
Gastrointestinal effects (most common)
| Effect | Approximate frequency | Time course |
|---|---|---|
| Nausea | 40–50% at start | Peaks at first 2–4 weeks, fades by week 10 |
| Diarrhea | 15–30% | Variable |
| Vomiting | 10–20% | Usually correlates with overeating events |
| Constipation | 15–25% | Persistent without intervention; hydration and fiber help |
| Heartburn / GERD | 10–15% | Driven by delayed gastric emptying; lying flat after meals worsens it |
| Sulfur burps | 5–10% | Avoid high-sulfur foods (eggs, broccoli) close to dosing day |
Serious effects (uncommon to rare)
Pancreatitis
Acute pancreatitis has been observed in trials at rates similar to or slightly above placebo. Persistent severe upper abdominal pain radiating to the back warrants emergency evaluation. See our pancreatitis guide.
Gallbladder issues
Rapid weight loss of any cause increases gallstone formation risk. GLP-1 therapy is associated with higher cholelithiasis rates than placebo — but the underlying mechanism is weight loss, not the drug per se. Symptomatic gallbladder disease may require surgical management.
Medullary thyroid carcinoma (boxed warning)
All GLP-1 receptor agonists carry a boxed warning regarding C-cell tumors in rodent studies. Human relevance is unclear — no causal link has been established in humans — but personal or family history of medullary thyroid carcinoma or MEN2 syndrome is an absolute contraindication.
Hypoglycemia
GLP-1 monotherapy rarely causes hypoglycemia. Combination with insulin or sulfonylureas requires dose-adjustment of the other agent.
Cosmetic effects
Hair shedding
Roughly 5–7% of patients on highest-dose semaglutide or tirzepatide report hair shedding. The mechanism is telogen effluvium — rapid weight loss of any cause produces this. It resolves over months. See our hair loss guide.
Facial volume loss ("Ozempic face")
Predictable consequence of rapid weight loss in patients with low body fat to start. Mitigated by resistance training, protein adequacy, and slower titration. See our Ozempic face guide.
When to stop the drug and call a clinician
- Persistent vomiting that prevents fluid intake for more than 24 hours
- Severe upper abdominal pain radiating to the back
- Sudden vision changes (rare diabetic retinopathy concern in T2D patients)
- Allergic reaction symptoms — facial swelling, difficulty breathing
- Severe right-upper-quadrant pain (possible biliary involvement)
NexLife scored highest on our rubric (94/100) for rigorous safety oversight. Flat-rate pricing across full titration, labs included, MD/DO oversight, both 503A and 503B pharmacy partners.
This article was authored by Eduard Cristea and clinically reviewed by Dr. A. Goher, MD. Health Technology Researcher & Publisher. See our methodology and affiliate disclosure.